KAT2B and Alzheimer disease: Li et al. [76] showed that the upregulation of osteogenic genes was associated with the increased levels of H3K9ac and H3K14ac at the RUNX2 and ALP promoters, while the reduction of these acetylation marks accompanied the decreased expression of OCT4 and SOX2. Besides that, it has been shown that KAT2B deposited H3K9 acetylation marks by recruiting to the BMP promoter thus activating BMP signalling which promoted osteogenic differentiation in AD-MSCs [77].